<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Mid-America Apartment Communit</title>
	<atom:link href="http://www.stockbloghub.com/tag/mid-america-apartment-communit/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MAA) Mid-America Apartment Communities&#8217; CFO to Retire</title>
		<link>http://www.stockbloghub.com/2009/09/01/maa-mid-america-apartment-communities-cfo-to-retire/14005</link>
		<comments>http://www.stockbloghub.com/2009/09/01/maa-mid-america-apartment-communities-cfo-to-retire/14005#comments</comments>
		<pubDate>Tue, 01 Sep 2009 17:33:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communit]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14005</guid>
		<description><![CDATA[Mid-America Apartment Communities Inc. (MAA), a self-administered and self-managed real estate investment trust (REIT), recently announced the retirement of its CFO Simon Wadsworth as part of the long-term succession-planning program. The company’s Executive Vice President, Treasurer and Director of Financial Planning Albert Campbell will replace Simon Wadsworth. Campbell joined Mid-America Apartment in 1998 as Vice President of Financial Planning and was later promoted to Senior Vice President and Treasurer of the company in 2003. Mid-America Apartment owns and manages apartments in the Sunbelt region of the U.S. The company defines its portfolio in two tiers– primary markets and secondary markets. Having a diversified presence in diverse markets helps mitigate risk and decreases volatility in the event of a slowdown in any one product type. Primary markets are relatively larger in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/maa-mid-america-apartment-communities-cfo-to-retire/14005/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) European Medicines Agency Accepts Merck&#8217;s Application</title>
		<link>http://www.stockbloghub.com/2009/08/27/maa-european-medicines-agency-accepts-mercks-application/13720</link>
		<comments>http://www.stockbloghub.com/2009/08/27/maa-european-medicines-agency-accepts-mercks-application/13720#comments</comments>
		<pubDate>Thu, 27 Aug 2009 23:56:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[Mid-America Apartment Communit]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13720</guid>
		<description><![CDATA[We are pleased to hear that the European Medicines Agency (EMEA) has agreed to review the Marketing Authorization Application (MAA) of Merck’s (MRK) vernakalant intravenous (IV). The company is seeking EMEA approval for the drug to address the unmet need for patients suffering from acute atrial fibrillation (AF, abnormal heart rhythms leading to strokes). Along with the IV version, Merck is also developing the oral form of the drug, which is currently in phase II development. In April 2009, Merck entered into a collaboration and licensing agreement with Cardiome Pharma Corp. in order to develop and commercialize vernakalant. While Merck retains the exclusive global rights to the oral formulation of vernakalant, its affiliate, MSD Switzerland GmbH gets the rights to the IV formulation outside the US, Canada and Mexico. Atrial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/maa-european-medicines-agency-accepts-mercks-application/13720/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) The Medicines Company Withdraws MAA</title>
		<link>http://www.stockbloghub.com/2009/08/21/maa-the-medicines-company-withdraws-maa/13105</link>
		<comments>http://www.stockbloghub.com/2009/08/21/maa-the-medicines-company-withdraws-maa/13105#comments</comments>
		<pubDate>Sat, 22 Aug 2009 01:57:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communit]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13105</guid>
		<description><![CDATA[Yesterday, The Medicines Company (MDCO) announced that it has withdrawn its European marketing authorization application (MAA) for the 200mg 3-7 day daily dose therapy of oritavancin. The company is developing oritavancin, a novel, semi-synthetic lipoglycopeptide antibiotic candidate for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram positive pathogens. Currently available therapies include Cubist Pharma’s (CBST) Cubicin. Oritavancin became a part of The Medicine Company’s pipeline following the February 2009 acquisition of Targanta Therapeutics. Oritavancin, if developed successfully, could be used in the hospital setting, most likely in the critical care setting in the intensive care unit (ICU), emergency department or surgical suite. It is primarily designed for patients with methicillin-resistant staphylococcus aureus (MRSA) or vancomycin resistant infections, which represents a large and underserved market. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/21/maa-the-medicines-company-withdraws-maa/13105/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

